Search clinical trials for: Vorinostat, Lenalinomide and Dexamethasone

Total 4549 results

Hackensack Meridian Health

Active, not recruiting

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (QUAD)

Multiple Myeloma

United States
Hackensack Meridian Health
Merck Sharp & Dohme LLC

Completed

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens (RZD)

Multiple Myeloma

United States
Johns Hopkins All Children's Hospital

Terminated

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

Central Nervous System Tumors

United States
University of Leeds
Merck Sharp & Dohme LLC; Celgene; Amgen

Unknown

Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)

Multiple Myeloma

United Kingdom
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC; Celgene Corporation

Terminated

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) (LenVoDex)

Peripheral T-Cell Non-Hodgkin's Lymphoma

Austria
City of Hope Medical Center

Terminated

Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Bristol-Myers Squibb

Completed

Dasatinib in Combination With Revlimid (and Dexamethasone)

Multiple Myeloma

United States, France, Australia
Samsung Medical Center
Seok Jin Kim

Terminated

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma (ZOLINZA)

Mantle Cell Lymphoma

Korea, Republic of
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene Corporation

Unknown

Lenalidomide in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

Austria
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (DSM XIII)

Multiple Myeloma

Germany
University of Leeds
Merck Sharp & Dohme LLC; Myeloma UK

Completed

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) (MUKfour)

Multiple Myeloma

United Kingdom
TJ Biopharma Co., Ltd.

Active, not recruiting

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

China, Taiwan
University Health Network, Toronto

Completed

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Multiple Myeloma | Renal Failure

Canada
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Merck Sharp & Dohme LLC

Terminated

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (VEIL)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

Australia
European Myeloma Network
Sanofi; Amgen; EMN Research Italy

Active, not recruiting

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia)

Multiple Myeloma

Czechia, Germany, Greece, Italy, Netherlands, Norway, Spain
University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
Samsung Medical Center

Active, not recruiting

Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma (KMM1910)

Multiple Myeloma

Korea, Republic of
Katy Peters
Merck Sharp & Dohme LLC; Genentech, Inc.

Completed

Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Glioblastoma | Brain Tumor

United States
Celgene Corporation

Terminated

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Canada, Australia
Children's Hospital Medical Center, Cincinnati
Bill and Melinda Gates Foundation; Syngene International

Completed

India Dexamethasone and Betamethasone

Preterm Birth | Antenatal Corticosteroids

India
Indiana University School of Medicine
Bayer

Completed

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Promyelocytic, Acute

United States
Seoul National University Bundang Hospital

Completed

Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone

Back Pain | Neck Pain

Korea, Republic of
Tiziana Marangon

Withdrawn

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy (ZLd_Ld)

Multiple Myeloma

Italy
Armando Santoro, MD

Terminated

Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC

Small Cell Lung Cancer

Italy
University of Oklahoma
Stony Brook University

Completed

Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"

Intraventricular Hemorrhage | Respiratory Distress Syndrome | Neonatal Mortality

United States
Merck Sharp & Dohme LLC

Completed

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Lymphoma
Ahmadu Bello University Teaching Hospital

Completed

Effect of Antenatal Corticosteroids on Neonatal Morbidity.

Neonatal Respiratory Distress Syndrome

Nigeria
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
The Methodist Hospital Research Institute

Withdrawn

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT)

Non-Hodgkin Lymphoma
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
Vaishali Sanchorawala
Celgene Corporation

Completed

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

MANTLE CELL LYMPHOMA

Italy
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

Cancer

United States
Peking Union Medical College Hospital

Recruiting

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

Rosai-Dorfman Disease

China
Istituto Clinico Humanitas

Unknown

The Treatment of Lenalidomide in Patients With POEMS Syndrome

POEMS Syndrome

Italy
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

Multiple Myeloma in Relapse

France
National Center for Tumor Diseases, Heidelberg
Merck Sharp & Dohme LLC; University Hospital Heidelberg

Completed

Vorinostat in Children

Children With Relapsed Solid Tumor, Lymphoma or Leukemia

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fox Chase Cancer Center
National Comprehensive Cancer Network

Completed

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (NSCLC)

Locally Advanced Non-small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Lymphoma | Leukemia | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Virginia Commonwealth University

Withdrawn

HDAC Inhibitor Augmentation to Clozapine

Schizophrenia

United States
University College, London

Completed

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (LenD)

Chronic Lymphocytic Leukemia

United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
Austrian Forum Against Cancer

Unknown

Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure

Multiple Myeloma Light Chain Induced Renal Insufficiency

Austria, Czech Republic
IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation

Completed

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Primary Plasma Cell Leukemia

Italy
Ciusss de L'Est de l'Île de Montréal
Celgene; C3i Center Inc.

Active, not recruiting

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Multiple Myeloma | Relapsed Hematologic Malignancy

Canada
Celgene

Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

Japan
Peking Union Medical College Hospital
Celgene Corporation

Completed

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

POEMS Syndrome

China

Search clinical trials for: Vorinostat, Lenalinomide and Dexamethasone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations